The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription o...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2024-06, Vol.24 (1), p.712-10
Main Authors: de Moraes, Francisco Cezar Aquino, Sudo, Renan Yuji Ura, Souza, Maria Eduarda Cavalcanti, Fernandes, Marianne Rodrigues, Dos Santos, Ney Pereira Carneiro
Format: Article
Language:English
Subjects:
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Bipolar disorder
Cancer
Cancer therapies
Citation management software
Complications and side effects
Depression, Mental
Diabetes
Dosage and administration
Drug Side effects
Endometrial cancer
Endometrial Neoplasms - chemically induced
Endometrial Neoplasms - epidemiology
Endometrium
Epidemiology
Female
Genital cancer
Genital Neoplasms, Female - drug therapy
Genital Neoplasms, Female - epidemiology
Gynecological cancer
Gynecology
Health aspects
Humans
Hypertension
Incidence
Mental disorders
Meta-analysis
Mortality
Observational studies
Odds Ratio
Oncology, Experimental
Online databases
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - epidemiology
Physiological aspects
Psychotropic drugs
Public health
Risk Factors
Schizophrenia
Statistical analysis
Statistics
Systematic review
Thioridazine
Trifluoperazine
Tumors
Uterine cancer
Vagina
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c516t-7595f418e67fdf289d4a32edf5ca48bade83fa21eba1f6e7aa5c281b56c4d2283
cites
container_end_page 10
container_issue 1
container_start_page 712
container_title BMC cancer
container_volume 24
creator de Moraes, Francisco Cezar Aquino
Sudo, Renan Yuji Ura
Souza, Maria Eduarda Cavalcanti
Fernandes, Marianne Rodrigues
Dos Santos, Ney Pereira Carneiro
description Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial. We searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of
doi_str_mv 10.1186/s12885-024-12481-6
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_89acb00832294f2f83c2f0f33e283964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A797291632</galeid><doaj_id>oai_doaj_org_article_89acb00832294f2f83c2f0f33e283964</doaj_id><sourcerecordid>A797291632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-7595f418e67fdf289d4a32edf5ca48bade83fa21eba1f6e7aa5c281b56c4d2283</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rr6B7yQgiAKds1Xk9QbWRY_BhYEXa_DaXrSydhJxqYV59-b3VllKpKLhHOe9z0fpCieUnJOqZZvEmVa1xVhoqJMaFrJe8UpFYpWTBB1_-h9UjxKaUMIVZroh8UJzzotuT4t7PUaSx-s7zBYLEefvpfRlf0-oI1D7L2FobSQc2PZ7ksIk9-lvV3HydtyTvi2hHKLE1QQYNgnn27UNXktCCt3MHkMU3pcPHAwJHxyd58V3z68v778VF19_ri6vLiqbE3lVKm6qZ2gGqVynWO66QRwhp2rLQjdQoeaO2AUW6BOogKoLdO0raUVHWOanxWrg28XYWN2o9_CuDcRvLkNxLE3MOa-BzS6AdsSojljjXDMaW6ZI45zzD6NFNnr3cFrN7db7GyeY4RhYbrMBL82ffxpKKWSq9tuXt45jPHHjGkyW58sDgMEjHMynEipGkqJyujzf9BNnMe80AOlNWnoEdVDnsAHF3Nhe2NqLlSjWJMLs0yd_4fKp8OttzGg8zm-ELxaCDIz4a-phzkls_r6Zcm-OGLXCMO0TnGYJx9DWoLPjtf3d29_Ph7_DWtq10I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066880917</pqid></control><display><type>article</type><title>The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>de Moraes, Francisco Cezar Aquino ; Sudo, Renan Yuji Ura ; Souza, Maria Eduarda Cavalcanti ; Fernandes, Marianne Rodrigues ; Dos Santos, Ney Pereira Carneiro</creator><creatorcontrib>de Moraes, Francisco Cezar Aquino ; Sudo, Renan Yuji Ura ; Souza, Maria Eduarda Cavalcanti ; Fernandes, Marianne Rodrigues ; Dos Santos, Ney Pereira Carneiro</creatorcontrib><description>Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial. We searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of &lt; 0.05 denoted statistically significant. 50,402 patients were included, of whom 778 (1,54%) took antipsychotic medication for at least 1 year. 1,086 (2,15%) with ovarian cancer and 49,316 (97,85%) with endometrial cancer. Antipsychotic use (OR 1.50; 1.06 to 2.13 95% CI; p-value 0.02), hypertension (OR 1.50; 95% CI 1.06 to 2.13; p-value &lt; 0.01), nulliparity (OR 1.98; 95% CI 1.53 to 2.57; p-value &lt; 0.01) and multiparity (OR 0.53; 95% CI 0.41 to 0.69; p-value &lt; 0.01) showed significantly different distributions between groups of cancer and cancer-free patients. The primary endpoint of incidence risk of gynecological cancer by antipsychotic therapy showed a statistically significant difference (OR 1.67; 95% CI 1.02 to 2.73; p-value &lt; 0.05) against the use of antipsychotic drugs. Our meta-analysis showed that the use of antipsychotic drugs increases the risk of gynecological cancers, particularly endometrial cancer. This result should be weighed against the potential effects of treatment for a balanced prescribing decision.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-024-12481-6</identifier><identifier>PMID: 38858638</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Antipsychotics ; Bipolar disorder ; Cancer ; Cancer therapies ; Citation management software ; Complications and side effects ; Depression, Mental ; Diabetes ; Dosage and administration ; Drug Side effects ; Endometrial cancer ; Endometrial Neoplasms - chemically induced ; Endometrial Neoplasms - epidemiology ; Endometrium ; Epidemiology ; Female ; Genital cancer ; Genital Neoplasms, Female - drug therapy ; Genital Neoplasms, Female - epidemiology ; Gynecological cancer ; Gynecology ; Health aspects ; Humans ; Hypertension ; Incidence ; Mental disorders ; Meta-analysis ; Mortality ; Observational studies ; Odds Ratio ; Oncology, Experimental ; Online databases ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - epidemiology ; Physiological aspects ; Psychotropic drugs ; Public health ; Risk Factors ; Schizophrenia ; Statistical analysis ; Statistics ; Systematic review ; Thioridazine ; Trifluoperazine ; Tumors ; Uterine cancer ; Vagina ; Womens health</subject><ispartof>BMC cancer, 2024-06, Vol.24 (1), p.712-10</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-7595f418e67fdf289d4a32edf5ca48bade83fa21eba1f6e7aa5c281b56c4d2283</citedby><orcidid>0000-0002-1396-3442 ; 0000-0001-8117-2784 ; 0000-0002-7244-6461 ; 0000-0001-8087-7037</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11163728/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3066880917?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38858638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Moraes, Francisco Cezar Aquino</creatorcontrib><creatorcontrib>Sudo, Renan Yuji Ura</creatorcontrib><creatorcontrib>Souza, Maria Eduarda Cavalcanti</creatorcontrib><creatorcontrib>Fernandes, Marianne Rodrigues</creatorcontrib><creatorcontrib>Dos Santos, Ney Pereira Carneiro</creatorcontrib><title>The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial. We searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of &lt; 0.05 denoted statistically significant. 50,402 patients were included, of whom 778 (1,54%) took antipsychotic medication for at least 1 year. 1,086 (2,15%) with ovarian cancer and 49,316 (97,85%) with endometrial cancer. Antipsychotic use (OR 1.50; 1.06 to 2.13 95% CI; p-value 0.02), hypertension (OR 1.50; 95% CI 1.06 to 2.13; p-value &lt; 0.01), nulliparity (OR 1.98; 95% CI 1.53 to 2.57; p-value &lt; 0.01) and multiparity (OR 0.53; 95% CI 0.41 to 0.69; p-value &lt; 0.01) showed significantly different distributions between groups of cancer and cancer-free patients. The primary endpoint of incidence risk of gynecological cancer by antipsychotic therapy showed a statistically significant difference (OR 1.67; 95% CI 1.02 to 2.73; p-value &lt; 0.05) against the use of antipsychotic drugs. Our meta-analysis showed that the use of antipsychotic drugs increases the risk of gynecological cancers, particularly endometrial cancer. This result should be weighed against the potential effects of treatment for a balanced prescribing decision.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Antipsychotics</subject><subject>Bipolar disorder</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Citation management software</subject><subject>Complications and side effects</subject><subject>Depression, Mental</subject><subject>Diabetes</subject><subject>Dosage and administration</subject><subject>Drug Side effects</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - chemically induced</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Endometrium</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Genital cancer</subject><subject>Genital Neoplasms, Female - drug therapy</subject><subject>Genital Neoplasms, Female - epidemiology</subject><subject>Gynecological cancer</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Incidence</subject><subject>Mental disorders</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Odds Ratio</subject><subject>Oncology, Experimental</subject><subject>Online databases</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Physiological aspects</subject><subject>Psychotropic drugs</subject><subject>Public health</subject><subject>Risk Factors</subject><subject>Schizophrenia</subject><subject>Statistical analysis</subject><subject>Statistics</subject><subject>Systematic review</subject><subject>Thioridazine</subject><subject>Trifluoperazine</subject><subject>Tumors</subject><subject>Uterine cancer</subject><subject>Vagina</subject><subject>Womens health</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7rr6B7yQgiAKds1Xk9QbWRY_BhYEXa_DaXrSydhJxqYV59-b3VllKpKLhHOe9z0fpCieUnJOqZZvEmVa1xVhoqJMaFrJe8UpFYpWTBB1_-h9UjxKaUMIVZroh8UJzzotuT4t7PUaSx-s7zBYLEefvpfRlf0-oI1D7L2FobSQc2PZ7ksIk9-lvV3HydtyTvi2hHKLE1QQYNgnn27UNXktCCt3MHkMU3pcPHAwJHxyd58V3z68v778VF19_ri6vLiqbE3lVKm6qZ2gGqVynWO66QRwhp2rLQjdQoeaO2AUW6BOogKoLdO0raUVHWOanxWrg28XYWN2o9_CuDcRvLkNxLE3MOa-BzS6AdsSojljjXDMaW6ZI45zzD6NFNnr3cFrN7db7GyeY4RhYbrMBL82ffxpKKWSq9tuXt45jPHHjGkyW58sDgMEjHMynEipGkqJyujzf9BNnMe80AOlNWnoEdVDnsAHF3Nhe2NqLlSjWJMLs0yd_4fKp8OttzGg8zm-ELxaCDIz4a-phzkls_r6Zcm-OGLXCMO0TnGYJx9DWoLPjtf3d29_Ph7_DWtq10I</recordid><startdate>20240610</startdate><enddate>20240610</enddate><creator>de Moraes, Francisco Cezar Aquino</creator><creator>Sudo, Renan Yuji Ura</creator><creator>Souza, Maria Eduarda Cavalcanti</creator><creator>Fernandes, Marianne Rodrigues</creator><creator>Dos Santos, Ney Pereira Carneiro</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1396-3442</orcidid><orcidid>https://orcid.org/0000-0001-8117-2784</orcidid><orcidid>https://orcid.org/0000-0002-7244-6461</orcidid><orcidid>https://orcid.org/0000-0001-8087-7037</orcidid></search><sort><creationdate>20240610</creationdate><title>The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients</title><author>de Moraes, Francisco Cezar Aquino ; Sudo, Renan Yuji Ura ; Souza, Maria Eduarda Cavalcanti ; Fernandes, Marianne Rodrigues ; Dos Santos, Ney Pereira Carneiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-7595f418e67fdf289d4a32edf5ca48bade83fa21eba1f6e7aa5c281b56c4d2283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Antipsychotics</topic><topic>Bipolar disorder</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Citation management software</topic><topic>Complications and side effects</topic><topic>Depression, Mental</topic><topic>Diabetes</topic><topic>Dosage and administration</topic><topic>Drug Side effects</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - chemically induced</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Endometrium</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Genital cancer</topic><topic>Genital Neoplasms, Female - drug therapy</topic><topic>Genital Neoplasms, Female - epidemiology</topic><topic>Gynecological cancer</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Incidence</topic><topic>Mental disorders</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Odds Ratio</topic><topic>Oncology, Experimental</topic><topic>Online databases</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Physiological aspects</topic><topic>Psychotropic drugs</topic><topic>Public health</topic><topic>Risk Factors</topic><topic>Schizophrenia</topic><topic>Statistical analysis</topic><topic>Statistics</topic><topic>Systematic review</topic><topic>Thioridazine</topic><topic>Trifluoperazine</topic><topic>Tumors</topic><topic>Uterine cancer</topic><topic>Vagina</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Moraes, Francisco Cezar Aquino</creatorcontrib><creatorcontrib>Sudo, Renan Yuji Ura</creatorcontrib><creatorcontrib>Souza, Maria Eduarda Cavalcanti</creatorcontrib><creatorcontrib>Fernandes, Marianne Rodrigues</creatorcontrib><creatorcontrib>Dos Santos, Ney Pereira Carneiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Moraes, Francisco Cezar Aquino</au><au>Sudo, Renan Yuji Ura</au><au>Souza, Maria Eduarda Cavalcanti</au><au>Fernandes, Marianne Rodrigues</au><au>Dos Santos, Ney Pereira Carneiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2024-06-10</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>712</spage><epage>10</epage><pages>712-10</pages><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Female gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial. We searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of &lt; 0.05 denoted statistically significant. 50,402 patients were included, of whom 778 (1,54%) took antipsychotic medication for at least 1 year. 1,086 (2,15%) with ovarian cancer and 49,316 (97,85%) with endometrial cancer. Antipsychotic use (OR 1.50; 1.06 to 2.13 95% CI; p-value 0.02), hypertension (OR 1.50; 95% CI 1.06 to 2.13; p-value &lt; 0.01), nulliparity (OR 1.98; 95% CI 1.53 to 2.57; p-value &lt; 0.01) and multiparity (OR 0.53; 95% CI 0.41 to 0.69; p-value &lt; 0.01) showed significantly different distributions between groups of cancer and cancer-free patients. The primary endpoint of incidence risk of gynecological cancer by antipsychotic therapy showed a statistically significant difference (OR 1.67; 95% CI 1.02 to 2.73; p-value &lt; 0.05) against the use of antipsychotic drugs. Our meta-analysis showed that the use of antipsychotic drugs increases the risk of gynecological cancers, particularly endometrial cancer. This result should be weighed against the potential effects of treatment for a balanced prescribing decision.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38858638</pmid><doi>10.1186/s12885-024-12481-6</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1396-3442</orcidid><orcidid>https://orcid.org/0000-0001-8117-2784</orcidid><orcidid>https://orcid.org/0000-0002-7244-6461</orcidid><orcidid>https://orcid.org/0000-0001-8087-7037</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2024-06, Vol.24 (1), p.712-10
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_89acb00832294f2f83c2f0f33e283964
source Publicly Available Content Database; PubMed Central
subjects Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Bipolar disorder
Cancer
Cancer therapies
Citation management software
Complications and side effects
Depression, Mental
Diabetes
Dosage and administration
Drug Side effects
Endometrial cancer
Endometrial Neoplasms - chemically induced
Endometrial Neoplasms - epidemiology
Endometrium
Epidemiology
Female
Genital cancer
Genital Neoplasms, Female - drug therapy
Genital Neoplasms, Female - epidemiology
Gynecological cancer
Gynecology
Health aspects
Humans
Hypertension
Incidence
Mental disorders
Meta-analysis
Mortality
Observational studies
Odds Ratio
Oncology, Experimental
Online databases
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - epidemiology
Physiological aspects
Psychotropic drugs
Public health
Risk Factors
Schizophrenia
Statistical analysis
Statistics
Systematic review
Thioridazine
Trifluoperazine
Tumors
Uterine cancer
Vagina
Womens health
title The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A39%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20incidence%20risk%20of%20gynecological%20cancer%20by%20antipsychotic%20use:%20a%20meta-analysis%20of%2050,402%20patients&rft.jtitle=BMC%20cancer&rft.au=de%20Moraes,%20Francisco%20Cezar%20Aquino&rft.date=2024-06-10&rft.volume=24&rft.issue=1&rft.spage=712&rft.epage=10&rft.pages=712-10&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-024-12481-6&rft_dat=%3Cgale_doaj_%3EA797291632%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c516t-7595f418e67fdf289d4a32edf5ca48bade83fa21eba1f6e7aa5c281b56c4d2283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3066880917&rft_id=info:pmid/38858638&rft_galeid=A797291632&rfr_iscdi=true